We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $162M
1-Year Est. Return 259.04%
This Fund
S&P 500
This Quarter Est. Return
+9.78%
1 Year Est. Return
+259.04%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$133M
AUM Growth
-$14.8M
Cap. Flow
-$12.1M
Cap. Flow %
-9.07%
Top 10 Hldgs %
36.98%
Holding
83
New
24
Increased
11
Reduced
18
Closed
24

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$5.46M
2
ARVN icon
Arvinas
ARVN
+$5.31M
3
HUM icon
Humana
HUM
+$4.85M
4
SLNO
Soleno Therapeutics
SLNO
+$4M
5
RLAY icon
Relay Therapeutics
RLAY
+$3.64M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$6.55M
2
TGTX icon
TG Therapeutics
TGTX
+$4.86M
3
ALGN icon
Align Technology
ALGN
+$4.76M
4
CI icon
Cigna
CI
+$4.23M
5
BNTX icon
BioNTech
BNTX
+$4.1M

Sector Composition

Rank Sector Weight
1 Healthcare 98.45%
2 Miscellaneous 1.32%
3 Financials 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$14.6B
$6.77M 5.09%
246,700
+35,700
+17% +$923K
LLY icon
2
Eli Lilly
LLY
$1.02T
$6.37M 4.78%
8,247
-2,200
-21% -$1.82M
GERN icon
3
Geron
GERN
$1.01B
$5.62M 4.22%
1,561,152
+656,026
+72% +$2.62M
HUM icon
4
Humana
HUM
$48.2B
$4.58M 3.44%
+18,066
New +$4.85M
GH icon
5
Guardant Health
GH
$21.7B
$4.52M 3.39%
147,800
+58,000
+65% +$1.63M
RLAY icon
6
Relay Therapeutics
RLAY
$4.17B
$4.46M 3.35%
1,083,487
+668,858
+161% +$3.64M
IRON icon
7
Disc Medicine
IRON
$3.04B
$4.38M 3.29%
69,072
+4,556
+7% +$264K
SNDX icon
8
Syndax Pharmaceuticals
SNDX
$1.84B
$4.22M 3.17%
+318,900
New +$5.46M
ARVN icon
9
Arvinas
ARVN
$614M
$4.19M 3.15%
+218,700
New +$5.31M
GPCR icon
10
Structure Therapeutics
GPCR
$3.38B
$4.12M 3.1%
151,965
+31,800
+26% +$1.13M
ISRG icon
11
Intuitive Surgical
ISRG
$130B
$3.88M 2.91%
7,427
– –
APLS
12
DELISTED
Apellis Pharmaceuticals
APLS
$3.81M 2.86%
119,467
+19,100
+19% +$574K
BMY icon
13
Bristol-Myers Squibb
BMY
$136B
$3.69M 2.77%
65,200
-12,800
-16% -$715K
BSX icon
14
Boston Scientific
BSX
$69.3B
$3.62M 2.72%
+40,500
New +$3.57M
NTRA icon
15
Natera
NTRA
$47.3B
$3.55M 2.67%
22,450
– –
SLNO
16
DELISTED
Soleno Therapeutics
SLNO
$3.47M 2.61%
+77,285
New +$4M
SRRK icon
17
Scholar Rock
SRRK
$6.74B
$3.35M 2.51%
77,439
-55,600
-42% -$1.81M
NUVL
18
DELISTED
Nuvalent
NUVL
$3.19M 2.39%
40,580
+20,635
+103% +$1.93M
CYTK icon
19
Cytokinetics
CYTK
$10.1B
$3.1M 2.33%
65,883
+7,300
+12% +$379K
BPMC
20
DELISTED
Blueprint Medicines
BPMC
$2.77M 2.08%
31,800
-4,900
-13% -$449K
GILD icon
21
Gilead Sciences
GILD
$187B
$2.74M 2.06%
29,700
-20,300
-41% -$1.83M
SMMT icon
22
Summit Therapeutics
SMMT
$14B
$2.33M 1.75%
+130,412
New +$2.53M
CNTA
23
DELISTED
Centessa Pharmaceuticals
CNTA
$2.31M 1.73%
137,716
-436
-0.3% -$7.22K
EWTX icon
24
Edgewise Therapeutics
EWTX
$4.68B
$2.18M 1.63%
81,473
+21,573
+36% +$687K
JANX icon
25
Janux Therapeutics
JANX
$1.24B
$2.15M 1.61%
+40,123
New +$2.12M
1
2 3 4

Similar funds

STCOSD
Sageworth Trust Company of South Dakota Sioux Falls, South Dakota $162M AUM 26.79% 1-Year Est. Return
CCA
Cruiser Capital Advisors Stamford, Connecticut $162M AUM 78.28% 1-Year Est. Return
MIM
Macroview Investment Management Bethesda, Maryland $162M AUM 22.52% 1-Year Est. Return
CFG
Cornerstone Financial Group Omaha, Nebraska $162M AUM 14.64% 1-Year Est. Return
TF
TME Financial Huntington Beach, California $162M AUM 16.23% 1-Year Est. Return
CCM
Candelo Capital Management New York $162M AUM 112.87% 1-Year Est. Return
RWA
Reicon Wealth Advisors Atlanta, Georgia $162M AUM
VB
Value Base Tel Aviv, Israel $162M AUM 2.31% 1-Year Est. Return

Exome Asset Management's Q4 2024 Portfolio in Review

As of Q4 2024, Exome Asset Management held 83 positions worth $133M, down 10% from $148M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Exome Asset Management withdrew a net $12.1M in Q4 2024, closing 24 positions and reducing 18 holdings. Its most notable exit was Ascendis Pharma A/S, an estimated $6.55M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Exome Asset Management opened a new position in Syndax Pharmaceuticals worth $4.22M.

  • Exome Asset Management's largest Q4 2024 buy was Syndax Pharmaceuticals: 318,900 shares worth $4.22M.
  • Exome Asset Management added most to Relay Therapeutics in Q4 2024, an estimated $3.64M increase.
  • Exome Asset Management's biggest Q4 2024 reduction was Mersana Therapeutics, cutting an estimated $2.08M.
  • Exome Asset Management fully exited Ascendis Pharma A/S in Q4 2024, selling an estimated $6.55M.
  • Exome Asset Management's ten largest holdings make up 37% of its $133M portfolio in Q4 2024.
  • Exome Asset Management opened 24 new positions and closed 24 in Q4 2024.
  • Exome Asset Management's portfolio value fell 10% quarter-over-quarter to $133M.

Based on Exome Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.